Introduction
============

In the mid-seventies, major efforts were focused on the identification of new natural cannabinoids isolated from preparations of *Cannabis sativa* and of other subspecies and varieties, such as *Cannabis indica* and *Cannabis ruderalis*. The two most abundant and most therapeutically relevant components of the plants are (--)-*trans*-Δ^9^--tetrahydrocannabinol (Δ^9^--THC) and (-)-cannabidiol (CBD) (**Figure [1](#F1){ref-type="fig"}**). Over these last two decades, the endocannabinoid system (ECS) related to the effects of *Cannabis sativa* has being emerging as target of pharmacotherapy showing very considerable physiological significance ([@B75]). This system includes two cannabinoid receptors (CB~1~ and CB~2~) and endogenous ligands named endocannabinoids ([@B66]; [@B83]). CB~1~ receptor is abundant in the brain, but to a less extend in peripheral tissues. CB~2~ receptor is mainly expressed in immune cells.

![Cannabidiol (CBD) and (--)-*trans*-Δ^9^--tetrahydrocannabinol (Δ^9^--THC).](fphar-08-00422-g001){#F1}

Δ^9^--THC is responsible for the psychoactive effects of *Cannabis sativa* mediated by the activation of CB~1~ receptor in the brain, whereas CBD is considered non-psychotropic. Currently, CBD is clinically used in association with Δ^9^--THC in a cannabis-based preparation (Sativex^®^) that contains equimolar content of both for managing neuropathic symptoms associated with multiple sclerosis ([@B30]). CBD as a single drug is currently generating considerable interest due to its beneficial neuroprotective ([@B31]; [@B109]; [@B48]), antiepileptic ([@B23]; [@B129]), hypoxia-ischemia ([@B57]; [@B81]), anxiolytic ([@B65]; [@B108]), antipsychotic ([@B10]), analgesic ([@B64]), anti-inflammatory ([@B105]; [@B15]), anti-asthmatic ([@B99]; [@B126]), and antitumor properties ([@B67]; [@B65]) among others([@B78]; [@B135]; [@B98]; [@B127]). In 2016, GW pharmaceuticals reported the first positive results of CBD (Epidiolex^®^) in phase III clinical trials for treatment-resistant seizure disorders, including Lennox--Gastaut and Dravet syndromes. An overview of regulatory approvals and clinical trials of CBD has been recently published ([@B29]).

The molecular targets involved in the diverse therapeutic properties produced by CBD are still not very well-understood ([@B80]). Unlike Δ^9^--THC, CBD does not bind to the orthosteric binding site of the CB~1~ and CB~2~ cannabinoid receptors ([@B71]). Despite this lack of orthosteric affinity, CBD has been shown to antagonize the effects of the CB~1~/CB~2~ agonists CP--55,940 and WIN55212 at the mouse CB~1~ and at the human CB~2~ receptors ([@B88]; [@B123]). Therefore, allosteric activity of CBD at these receptors has been hypothesized. In a recent report, CBD was shown to be a negative allosteric modulator of Δ^9^--THC and the endogenous cannabinoid 2--AG providing a possible explanation for some *in vivo* CBD effects ([@B58]; [@B79]). CBD has also been shown to modulate endocannabinoid tone by inhibiting the cellular uptake of the endocannabinoid anandamide ([@B61]). This effect has been attributed to the fact that CBD competes with anandamide for binding to fatty acid-binding proteins (FABPs) which are intracellular proteins involved in the transport of anandamide to its metabolic enzyme fatty acid amide hydrolase (FAAH) ([@B25]). Other possible molecular targets of CBD have been explored. Modulation of the GPR55 receptor by CBD has been evaluated in different signaling pathway assays. CBD acts as an antagonist preventing \[^35^S\]GTPγS binding and Rho activation ([@B107]; [@B128]; [@B33]), modulating Ca^2+^ mobilization ([@B59]) and β-arrestin recruitment ([@B134]). CBD has also been proposed as an antagonist of the GPR18 cannabinoid receptor ([@B68], [@B69]). Certain actions of CBD such as anti-inflammatory and immunosuppressive effects appear to be partially mediated through the serotonin and adenosine receptors that are not considered part of the ECS. For instance, CBD acts as a full 5-HT~1A~ agonist, 5-HT~2A~ weak partial agonist and a non-competitive 5HT~3A~ antagonist ([@B106]; [@B133]; [@B101]). The ability of CBD to activate the A~1A~ adenosine receptor has also been proposed ([@B38]). Other molecular targets have also been studied, among them, the PPARγ nuclear receptors ([@B87]; [@B28]; [@B109]), glycine receptors ([@B1]; [@B130]), GABA~A~ receptors ([@B7]), and transient receptor potential (TRP) channels ([@B21], [@B22]). Studies focused on the possible epigenetic regulation of skin differentiation genes by CBD revealed that CBD is a transcriptional repressor that can control cell proliferation and differentiation through DNA methylation ([@B92]). Despite all of this data, the mechanistic bases for the effects of CBD remain complex.

Cannabidiol constitutes one of the most important components of therapeutic interest from *Cannabis sativa*. However, unlike the numerous synthesized cannabimimetics generated to provide a synthetic alternative to THC, CBD derivatives have only been superficially explored. The purpose of this review is to provide a structural overlook at natural and synthetic CBD derivatives. Due to the fact that diverse molecular targets are involved in the therapeutic properties produced by CBD, we associated CBD structures to their biological targets. Thus, this review is intended to be a useful tool especially for medicinal chemists.

The basic structure of the CBD derivatives described in this review consists of 5-alkyl resorcinols substituted in position 2 by a propenylcyclohexene. Structural modifications on the alkyl side-chain, on the propenylcyclohexene, and substitution of the phenolic hydroxyl groups are concerned. Quinone CBD analogs are also included in this classification as far as their structures are closely related to CBD.

Natural Cannabidiol Derivatives
===============================

In a recently published review dedicated to the diversity of cannabis phytocannabinoids, the authors updated the inventory of naturally occurring CBD derivatives ([@B41]). Herein, we are associating these structures to their possible molecular targets.

Of the over 100 natural cannabinoids identified in *Cannabis Sativa*, seven have been classified as CBD-type compounds including CBD (**Figure [2](#F2){ref-type="fig"}**) ([@B27]; [@B26]; [@B2]). All of them have the same absolute configuration than CBD; they are 5′-methyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-\[1,1′-biphenyl\]-2,6-dioles retaining the *trans*-(1*R*,6*R*) configuration. Cannabidiolic acid (CBDA) and cannabidivarinic acid (CBDVA-C3) are C3′-carboxylic derivatives, whereas cannabidiorcol (CBD-C1), cannabidiol-C4 also named as *nor*-cannabidiol (CBD-C4), and cannabidivarin (CBDV) differ from CBD by the length of their C4′-side chain. Cannabidiol monomethyl ether (CBDM), the C6′-methoxy CBD analog, was also isolated from the plant. Despite the potential therapeutic interest of these naturally occurring CBD derivatives, only a few related pharmacological studies have been reported (**Table [1](#T1){ref-type="table"}**). Like most non-steroidal anti-inflammatory drugs, CBDA is characterized by a carboxylic group resulting in a selective inhibition of cyclooxygenase-2 ([@B118]). CBDA does not have effect on anandamide inactivation in FAAH assays (Inhibition of \[^14^C\]-anandamide uptake: IC~50~ \> 50 μM) contrary to CBD (IC~50~ = 28 μM) ([@B11]; [@B63]). Other molecular targets proposed for CBDA include GPR55 ([@B3]) and TRPA1 with moderate activity ([@B21]). CBDA has been shown to be an inhibitor of cell migration in the highly aggressive human breast cancer MDA-MB-231 by alteration of Rho GTPase activity ([@B119]). CBDV, the C4′-propyl analog of CBD, displays very weak affinity for CB~1~ and CB~2~ receptors ([@B46]; [@B103]), whereas it has been reported to inhibit the activity of the putative endogenous ligand LPI in *h*GPR55-HEK293 cells ([@B3]). CBDV also targets the human TRPA1 channel ([@B21], [@B22]). In several animal seizures models, CBDV exerted notable anticonvulsant effects without affecting normal motor function ([@B45]). The mechanisms through which CBDV exerts its antiepileptic effects are uncertain ([@B50]). CBDV is currently in Phase II clinical trials as an antiepileptic drug under the name GWP42006.^[1](#fn01){ref-type="fn"}^

###### 

CB~1~/CB~2~ cannabinoid receptor binding, molecular targets and therapeutic potential of CBD derivatives.

  Compounds                     CB~1~R *K*~i~ \[nM\]   CB~2~R *K*~i~ \[nM\]   Reference   Other targets                                                                                  Therapeutic potential                                         Reference
  ----------------------------- ---------------------- ---------------------- ----------- ---------------------------------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------
  (-)-CBD                       \>10000                \>10000                [@B11]      NAM-CB1; FABPs; GPR55; GPR18; 5-HT~1A~; 5-HT~2A~; 5-HT~3A~; GlyR A~1A~; PPARγ; GABA~A~, TRPs   Neuroprotection; epilepsy; anxiety; psychosis; inflammation   [@B29]; [@B80]
  (-)-CBDA                                                                                COX-2; TRPA1; DAGLα                                                                            Inflammation; cancer; bacteria                                [@B5]; [@B118], [@B119]; [@B21]
  (-)-CBDV                      14711 ± 5734           574.2 ± 146            [@B103]     GPR55; TRPA1; CYP1A1                                                                           Convulsion; epilepsy                                          [@B21]; [@B3]; [@B45], [@B46]; [@B132]; [@B103]; [@B50]
  Machaeridol B                 \-                     \-                                 \-                                                                                             *Plasmodium falciparum*; *Leishmania donovani*                [@B82]
  Ferruginene C                 NR                     Weak                   [@B110]     TRPA1                                                                                          Cancer                                                        [@B110]
  (-)-7-OH-CBD                  \>10000                \>10000                [@B11]      \-                                                                                                                                                           
  (+)-7-OH-CBD                  5.3 ± 0.5              101.0 ± 5.1            [@B34]      \-                                                                                             \-                                                            
  (-)-7-COOH-CBD                \>10000                \>10000                [@B11]      \-                                                                                             \-                                                            
  (+)-7-COOH-CBD                13.2 ± 0.4             312.8 ± 15.8           [@B34]      \-                                                                                             \-                                                            
  CBE                           \-                     \-                                 CYP1A1                                                                                         \-                                                            [@B132]
  (+)-CBD                       842 ± 36               203 ± 16               [@B11]      \-                                                                                             \-                                                            
  H~2~-CBD                      \>1000                 \-                     [@B8]       \-                                                                                             Inflammation                                                  [@B8]
  H~4~-CBD                      145                    \-                     [@B8]       \-                                                                                             Inflammation                                                  [@B8]
  HU-444                        \>10000                \>10000                [@B39]      \-                                                                                             Inflammation                                                  [@B39]
  HU-446                        ∼1000                  \>10000                [@B55]      \-                                                                                             Inflammation                                                  [@B39]
  HU-465                        76.7 ± 58              12.1 ± 2.3             [@B55]      \-                                                                                             Inflammation                                                  [@B39]
  (-)-DMH-CBD                   \>10000                \>1000                 [@B11]      \-                                                                                             Anxiety; pain; inflammation; cancer                           [@B15]; [@B51]
  (+)-DMH-CBD                   17.4 ± 1.8             211 ± 23               [@B11]      \-                                                                                             \-                                                            
  (-)-7-OH-DMH-CBD              \>4000                 671 ± 12               [@B11]      TRPV1, opioid, α~2~-AR                                                                         \-                                                            [@B35]; [@B89]
  (+)-7-OH-DMH-CBD              2.5 ± 0.03             44.0 ± 3.1             [@B11]      \-                                                                                             \-                                                            
  (-)-7-COOH-DMH-CBD (HU-320)   \> 1000                \>4000                 [@B11]      \-                                                                                             Inflammation, immunosuppression                               [@B114]
  (+)-7-COOH-DMH-CBD            5.8 ± 0.7              155.5 ± 5.3            [@B34]      \-                                                                                             \-                                                            
  H~2~-DMH-CBD                  124                    \-                     [@B8]       \-                                                                                                                                                           
  H~4~-DMH-CBD                  17                     \-                     [@B8]       \-                                                                                                                                                           
  HU-308                        \>10000                22.7 ± 3.9             [@B40]      \-                                                                                             Inflammation; hepatic ischemia; osteoporosis; pain            [@B85]; [@B93],[@B94]; [@B15]
  (-)-CBDD                      \>10000                \>10000                [@B42]      15-LOX                                                                                         Atherosclerosis, body weight regulation                       [@B120], [@B116], [@B117]
  (+)-CBDD                      \>10000                \>10000                [@B42]      \-                                                                                             \-                                                            
  (-)-DMH-CBDD                  \>10000                \>10000                [@B42]      \-                                                                                             \-                                                            
  (+)-DMH-CBDD                  \>10000                \<10000                [@B42]      \-                                                                                             \-                                                            
  KLS-13019                     \-                     \-                                                                                                                                Neuroprotection                                               [@B52]
  HUF-101                       \-                     \-                                 \-                                                                                             Anxiety; depression, psychosis; convulsion                    [@B14]
  CBD-aldehyde-diacetate        \-                     \-                                 \-                                                                                             Convulsion                                                    [@B16]
  6-Oxo-CBD-diacetate           \-                     \-                                 \-                                                                                             Convulsion                                                    [@B16]
  6-OH-CBD-triacetate           \-                     \-                                 \-                                                                                             Convulsion                                                    [@B16]
  9-OH-CBD-triacetate           \-                     \-                                 \-                                                                                             Convulsion                                                    [@B16]
  HU-331                        NR                     NR                     [@B53]      Topoisomerase IIα; Caspases; ROS; PARP                                                         Cancer                                                        [@B53], [@B54]; [@B91]; [@B96]
  CBD-Q (V)                     \-                     \-                                 PPARγ                                                                                          Neuroprotection                                               [@B4]
  CBD-Q (VIII)                  \-                     \-                                 PPARγ                                                                                          Neuroprotection                                               [@B4]
  Abn-CBD                       \-                     \-                                 GPR55; GPR18                                                                                   Vasodilatation; bacteria; diabetes; colitis                   [@B49]; [@B107]; [@B5]; [@B20]; [@B56]; [@B70]
  O-1602                        NR                     NR                                 GPR55; GPR18                                                                                   Central nervous system; metabolism                            [@B49]; [@B102]; [@B6]; [@B20]
  CBG                           897 ± 596              153 ± 42               [@B103]     α~2~-AR; TRP; COX-1; COX-2; 5-HT~1A~                                                           Bacteria; bowel inflammation; depression                      [@B5]; [@B18]; [@B24]; [@B21]; [@B104]; [@B13]; [@B103]
  Cannabimovone                 \>10000                \>10000                [@B115]     TPRV1                                                                                          \-                                                            [@B115]
                                                                                                                                                                                                                                                       

NR, no response.

![Natural phytocannabinoid CBD analogs.](fphar-08-00422-g002){#F2}

Two aromatic analogs of CBD have been isolated from Lebanese hashish ([@B27]): cannabinodiol (CBND-C5), and cannabinodivarin (CBND-C3) (**Figure [3](#F3){ref-type="fig"}**) whose structural elucidation required their total synthesis ([@B100]). CBND-C~5~ found in the plant's flowers in low concentration, is considered a product of CBD photochemical conversion.

![Aromatic analogs of CBD.](fphar-08-00422-g003){#F3}

The conversion of CBD into human metabolites has been the subject of a recent interesting review ([@B124]). CBD biotransformation shows considerable species variability. The main biotransformation, including hydroxylation and oxidation, involves the CYP450 enzyme family. While 7-hydroxy-CBD (7-OH-CBD) derivatives are found in low concentration, the most abundant metabolites are hydroxylated 7-carboxylic acid derivatives of CBD (7-COOH-CBD, **Figure [4](#F4){ref-type="fig"}**). Glucuronidation of CBD seems to frequently occur at the phenolic oxygen (**Figure [4](#F4){ref-type="fig"}**). Another cannabinoid metabolite, the so called cannabielsoin (CBE), has been identified in plants as a product of photo-oxidation from CBD and CBDA ([@B111]; [@B124]), or by biotransformation using tissue cultures under normal growth conditions ([@B43]; [@B131]). CBE was also identified as a metabolite in guinea pigs, mice, rabbits, and rats ([@B131]). Despite the fact that CBD metabolites have been the subject of many studies, few *in vivo* studies have been published. Therefore, their therapeutic benefits remain to be established.

![Selected metabolites of CBD.](fphar-08-00422-g004){#F4}

Beyond the *Cannabis* plant, other naturally occuring products have been reported to interact with the ECS ([@B37]). However, only few of them are CBD-based compounds. Isolation and characterization of (+)-*trans*-hexahydrodibenzopyrans from the stem bark of the Amazonian liana *Machaerium multiflorum* Spruce led to the identification of the CBD related structures machaeridiols A, B, and C (**Figure [5](#F5){ref-type="fig"}**) ([@B82]). The total synthesis of these compounds via an efficient highly regio- and stereoselective approach has also been described ([@B47]). Although their activity at the CB~1~ and CB~2~ cannabinoid receptors has not been reported, these compounds displayed antimicrobial, antifungal, and antiparasitic activity in diverse *in vitro* assays ([@B82]). Machaeridiol B stands out as the most potent inhibitor against *Plasmodium falciparum* \[chloroquine-sensitive (D6) and chloroquine-resistant (W2) clones\] and *Leishmania donovani* with IC~50~ values in the low micromolar range (**Table [1](#T1){ref-type="table"}**).

![Cannabidiol (CBD)-related *Machaerium multiflorum*, *Rhododendron ferrugineum* L. and, *Lindera umbellata* Thunb. compounds.](fphar-08-00422-g005){#F5}

Ferruginene C, a methylpentanol derivative of CBD (**Figure [5](#F5){ref-type="fig"}**), was recently isolated from the leaves of *Rhododendron ferrugineum* L. as a mixture of diastereoisomers ([@B110]). Ferruginene C has been shown to be cytotoxic in the HL-60 cancer cell-line (IC~50~ 13.7 μM) with selectivity toward non-cancerous cell-line. It binds weakly to CB~2~ and TPRV1 receptors, but it did not show significant affinity for CB~1~ and 5-HT~1A~ receptors (**Table [1](#T1){ref-type="table"}**).

Even though linderatin (**Figure [5](#F5){ref-type="fig"}**), isolated from fresh leaves of *Lindera umbellata* Thunb. ([@B121]), is not considered a phytocannabinoid ([@B41]), it is interesting to include in the present review since closely related to CBD. No biological data have been reported so far.

Synthetic Cbd Analogs
=====================

Due to the promising therapeutic effects of CBD in a wide variety of diseases, synthetic CBD derivatives have attracted the attention of drug discovery programs in both industry and academia with the aim to improve the potency, efficacy, or pharmacokinetic properties of this interesting phytocannabinoid.

Synthetic approaches for different CBD metabolites such as 7-COOH-CBD or 7-OH-CBD (**Figure [4](#F4){ref-type="fig"}**) have been reported ([@B122]; [@B74]). Moreover, structural modifications on different pharmacophoric positions such as the lipophilic side chain, the phenolic hydroxyl groups or the C7-methyl have been widely accomplished. In addition to the (-)-CBD enantiomers, the (+)-CBD derivatives \[(+)-CBD depicted in **Figure [6](#F6){ref-type="fig"}**\] have also been synthesized and pharmacologically evaluated ([@B11]; [@B34]; [@B42]). Measurements of the binding affinities of these compounds for the CB~1~ and CB~2~ cannabinoid receptors yielded unexpected outcomes. Contrary to the naturally occurring (-)-CBD analogs, which showed no orthosteric affinity, most of the compounds in the (+)-CBD series bind to both receptors displaying selectivity toward CB~1~ (**Table [1](#T1){ref-type="table"}**).

![(+)-CBD and hydrogenated CBD derivatives.](fphar-08-00422-g006){#F6}

Hydrogenation of CBD yielded the dihydro- and tetrahydro-cannabidiol derivatives H~2~-CBD and H~4~-CBD (**Figure [6](#F6){ref-type="fig"}**) ([@B8]). Their effects on the production of reactive oxygen intermediates, nitric oxide, and tumor necrosis factor showed their anti-inflammatory capacity. In contrast to CBD, H~2~-CBD, and H~4~-CBD have affinity for the cannabinoid CB~1~ receptor (**Table [1](#T1){ref-type="table"}**). Additionally, the (-)- and (+)-dihydro-7-hydroxy-CBD enantiomers (HU-446 and HU-465, **Figure [6](#F6){ref-type="fig"}**) have recently been synthesized and biologically characterized in an inflammatory model of encephalitogenic T cells ([@B55]). Both compounds showed anti-inflammatory potential in inflammatory and autoimmune diseases models. However, only the (+)-enantiomer (HU-465) displays affinity for the cannabinoid CB~1~ and CB~2~ receptors (**Table [1](#T1){ref-type="table"}**).

1′,1′ -Dimethylheptyl-CBD Derivatives
-------------------------------------

Taking into account that substitution of the pentyl chain of Δ^9^--THC by a 1′, 1′-dimethylheptyl (DMH) lipophilic alkyl chain resulted in more active compounds than natural Δ^9^--THC ([@B73]), a similar approach was performed for the CBD scaffold ([@B77]; [@B42]) (**Table [1](#T1){ref-type="table"}**). Thus, the synthesis of DMH-CBD derivatives, such as DMH-CBD, HU-320, DMH-CBDD, and 7-OH-DMH-CBD (**Figure [7](#F7){ref-type="fig"}**) have been reported by Mechoulam and coworkers ([@B60]; [@B42]). Introduction of the DMH alkyl chain in the (-)-DMH-CBD series did not change the lack of CB~1~ and CB~2~ receptor affinity except for (-)-7-OH-DMH-CBD that moderately binds to CB~2~ (**Table [1](#T1){ref-type="table"}**) ([@B11]). However, in the case of the (+)-DMH-CBD series, the presence of the DMH alkyl chain improved both CB~1~ receptor affinity compared to (+)-CBD (**Table [1](#T1){ref-type="table"}**). (-)-DMH-CBD analogs have displayed anxiolytic, analgesic, anti-inflammatory, or antiproliferative effects in diverse assays ([@B15]). For instance, (-)-DMH-CBD has shown anti-inflammatory and antiproliferative properties in human acute myeloid leukemia, microglial or encephalitogenic T cells ([@B51]). The carboxylic acid HU-320 produced strong anti-inflammatory and immunosuppressive effects in an *in vivo* model of collagen-induced arthritis ([@B114]). Interestingly, (-)-7-OH-DMH-CBD exhibited potent inhibition of electrically evoked contractions of the mouse vas deferens that was not mediated through CB~1~, CB~2~, TRPV1, opioid, or α~2~-adrenergic receptors ([@B35]; [@B89]).

![Dimethylheptyl (DMH)-CBD derivatives.](fphar-08-00422-g007){#F7}

As previously mentioned for the pentyl CBD derivatives, hydrogenation of DMH-CBD has been studied ([@B8]). Partial hydrogenation gave H~2~-DMH-CBD (**Figure [7](#F7){ref-type="fig"}**) as the major epimer (hydrogenation at C8) with small amounts of the hydrogenated C1 epimer being obtained. Full hydrogenation allowed the formation of H~4~-DMH-CBD (**Figure [7](#F7){ref-type="fig"}**). These hydrogenated compounds, which bind to the CB~1~ receptor with affinity constants in the nanomolar range, displayed weak anti-inflammatory effects when compared to CBD or DMH-CBD.

The pinene dimethoxy-DMH-CBD derivative HU-308 (**Figure [7](#F7){ref-type="fig"}**) was identified decades ago as a potent peripheral CB~2~-selective agonist ([@B77]; [@B40]). HU-308 has shown very interesting properties such as anti-inflammatory, analgesic, neuroprotective or antitumor effects, and has been used as a pharmacological tool in numerous cannabinoid studies contributing to the progress in this field (e.g., [@B40]; [@B85]; [@B93],[@B94]; [@B15]). More recently, the efficacy of HU-308 and HU-433, two enantiomers, has been tested in ovariectomy-induced bone loss and ear inflammation ([@B112]) showing an inverse relationship between binding affinity and biological potency.

Other Modifications on the C4′-Alkyl Chain
------------------------------------------

In order to improve oral bioavailability and solubility issues, a novel series of CBD analogs have recently been synthesized ([@B52]) (**Figure [8](#F8){ref-type="fig"}**). Structural modifications at the pharmacophoric lipophilic chain allowed fine-tuning the "drug-likeness" of this scaffold by variation of different physicochemical parameters such as the number of hydrogen bond donors, acceptors, and polar surface area. Among these new derivatives depicted in **Figure [8](#F8){ref-type="fig"}**, KLS-13019 stands out as being 50-fold more potent and more than 400-fold safer than CBD preventing damage to hippocampal neurons induced by ammonium acetate and ethanol with improved oral bioavailability compared to CBD ([@B52]).

![Cannabidiol analogs modified on the C4′-alkyl chain.](fphar-08-00422-g008){#F8}

Halogenated CBD Derivatives
---------------------------

Structural modifications of CBD include halogenated substituents on the phenol ring. The first reported halogenations occurred at the 3′ and/or 5′ positions by chlorine, bromine or iodine substitution, allowing the preparation of 3′-Cl-CBD, 3′,5′-diCl-CBD, 3′-Br-CBD, 3′,5′-diBr-CBD, 3′-I-CBD, and 3′,5′-diI-CBD (**Figure [9](#F9){ref-type="fig"}**) ([@B125]). These halogenated compounds were evaluated in murine models of barbiturate-induced sleep prolongation, electroshock-induced seizures and locomotor activity resulting in activity similar to CBD for the monohalogenated analogs, whereas the dihalogenated derivatives displayed lower activity (**Table [1](#T1){ref-type="table"}**).

![Chlorinated, brominated, and iodinated CBD derivatives.](fphar-08-00422-g009){#F9}

The synthesis and pharmacological evaluation of three new fluorine halogenated CBD derivatives have been reported ([@B14]). Two of these were fluorinated at the cyclohexenyl ring substituent (**Figure [10](#F10){ref-type="fig"}**: HUF-102 and HUF-103), and the third one was fluorinated at the phenol ring (HUF-101). HUF-101 displayed the most promising results in four mice behavioral assays (elevated plus-maze, forced swimming test, prepulse inhibition, and marble burying test) that target anxiolytic, antidepressant, antipsychotic and anticompulsive activity respectively. HUF-101 may be an interesting prototype for further development since it showed higher potency than CBD in the animal assays cited above. In these tests, HUF-102 did not show activity at the doses tested (1--10 mg/kg), whereas HUF-103 showed moderate to low activity compared to HUF-101.

![Fluorinated CBD derivatives.](fphar-08-00422-g010){#F10}

Modifications on the Hydroxyl Groups
------------------------------------

Modifications on the resorcinol hydroxyl groups have been explored. Computational studies suggested that the removal of one of the CBD hydroxyl groups may enable the ligand to reach the CB~1~ binding site ([@B97]). Thus, desoxy-CBD represented in **Figure [11](#F11){ref-type="fig"}** was synthesized and evaluated. Pharmacological data for desoxy-CBD corroborated the computational studies showing CB~1~ partial agonism in the mouse vas deferens assay.

![Cannabidiol derivatives modified at the hydroxyl groups.](fphar-08-00422-g011){#F11}

Different research groups have developed acetylations and alkylations at one or both phenolic hydroxyls. For instance, the dimethylated CBD derivative named CBDD (**Figure [11](#F11){ref-type="fig"}**), as well as the monomethylated derivative (CBD-2′-monomethylether o *O*-methylcannabidiol) revealed higher potency and selectivity as 15-lipoxygenase inhibitors compared to CBD ([@B120], [@B116]). Consequently, the resorcinol moiety seems to be a determinant for the activity in this target. Further studies performed with CBDD suggest that this compound is not only a potential prototype for atherosclerosis treatment, but also a pharmacological tool to study the mechanisms of body weight regulation ([@B117]). Other alkylations on the phenolic hydroxyl group have been reported such as *O*-propyl- and *O*-pentylcannabidiol that have been structurally characterized but no pharmacological data have been described so far ([@B44]).

Cannabidiol derivatives bearing one or both hydroxyl substitutions have been reported in the patent literature to be active as anti-inflammatory agents ([@B76]). Selected examples disclosed in this patent (HU-410, HU-427, and HU-432) are depicted in **Figure [11](#F11){ref-type="fig"}**. It is interesting to highlight that some of these compounds present improved solubility, stability and bioavailability parameters when compared with CBD. Likewise, the non-CB~1~, non-CB~2~ ligand HU-444 has shown anti-inflammatory properties *in vitro* and *in vivo* in a murine model of collagen-induced arthritis ([@B39]).

In addition, the *in vivo* anticonvulsant activity of four diacetylated-CBD analogs (CBD-aldehyde-diacetate, 6-oxo-CBD-diacetate, 6-hydroxy-CBD-triacetate, and 9-hydroxy-CBD-triacetate, **Figure [12](#F12){ref-type="fig"}**) was demonstrated in a mouse model ([@B16]). Their effects against maximal electroshock convulsions, potentiation of pentobarbital sleeping-time and reduction of spontaneous motor activity were evaluated obtaining significant anticonvulsant effects at high doses. It is noteworthy that the safety, efficiency, and potency of these four compounds were lower than that of CBD in the same assays.

![Diacetylated-CBD analogs.](fphar-08-00422-g012){#F12}

At that point it is interesting to mention that these diacetate CBD derivatives could have been considered as prodrugs. Considering that CBD is rapidly distributed in adipose tissues and it undergoes a CYP3A- and CYP2C- dependent first-pass metabolism to give 7-hydroxy-CBD ([@B29]), a prodrug concept could be very useful. Therefore, the phenyl acetate groups could be deacetylated to give CBD. The pharmaceutical company, AllTranz, now called Zyberba Pharmaceutics, developed transdermal solutions of CBD-esters and -carbonates among others. The dicarbonate All00102 and the diglicolate AL00147 shown in **Figure [11](#F11){ref-type="fig"}** are two examples disclosed in a AllTranz's patent ([@B113]). Another company, Kalytera Therapeutics is currently undertaking the preclinical stage of K-1012, a bi-phosphate derivative of CBD designed as a prodrug indicated for acute respiratory distress syndrome.^[2](#fn02){ref-type="fn"}^

Quinone Derivatives of CBD
--------------------------

The quinone derivative of CBD, HU331, was first synthesized in [@B72] by oxidation of CBD. HU331 has been suggested to be a CBD metabolite having inhibitory effect on cytochrome P450 ([@B12]). It was not until [@B53] that the antineoplastic activity of HU-331 was reported. HU-331 was very effective in reducing growth of human colon carcinoma HT-29 cells in nude mice. The mechanism by which HU-331 acts as an antitumor agent is independent of the CB~1~ and CB~2~ cannabinoid receptors. HU-331 does not promote cell death via cell cycle arrest, cell apoptosis, or caspase activation. Extensive studies have shown that HU-331 anticancer properties were due to selective inhibition of the ATPase function of human topoisomerase IIα ([@B54]; [@B90]; [@B96]). Thus, HU-331 with a selective topoisomerase inhibition is expected to have less off-target toxicity than doxorubicin which antitumor activity is mediated through numerous mechanisms, such as apoptosis, abrogation of the cell cycle, activation of caspases, generation of ROS, and inhibition of both topoisomerases among others.

Structural modifications realized on the substituents of HU-331 led to the benzoquinones having anti-proliferative activity against diverse cancer cell lines ([@B91]). Unlike HU-331, benzoquinone mechanism of action involves caspase activation, poly-(ADP-ribose)-polymerase (PARP) protein cleavage, and reactive oxygen species (ROS) production. These data show the influence of CBD structure compared to the quinone core on the processes producing anticancer effects.

A recent patent from VivaCell Technology discloses HU-331 analogs which act as PPARγ agonists showing a neuroprotective profile in different models ([@B4]). The disclosed quinones are substituted in position 3′ by different amines or carboxylates that were synthesized by amination of CBD or esterification of CBDA respectively. Compounds CBD-Q (V) and CBD-Q (VIII) illustrated in **Figure [13](#F13){ref-type="fig"}** are representative of the HU-331 analogs.

![Quinones related to CBD.](fphar-08-00422-g013){#F13}

Miscellaneous CBD Derivatives
-----------------------------

Abnormal cannabidiol (Abn-CBD) ([@B95]), a non-psychoactive synthetic regioisomer of CBD (**Figure [14](#F14){ref-type="fig"}**), has been the subject of numerous studies that have shown Abn-CBD therapeutic potential as a vasodilator ([@B49]), antibacterial ([@B5]), antidiabetic ([@B70]), or anti-colitis agent ([@B56]). Recently, two molecular targets, GPR55 and GPR18, have been identified for Abn-CBD ([@B49]; [@B107]; [@B20]). Abn-CBD stimulated \[^35^S\]GTPγS binding at GPR55 ([@B86]) and increased calcium mobilization and ERK1/2 phosphorylation at GPR18 ([@B20]).

![Miscellaneous CBD derivatives.](fphar-08-00422-g014){#F14}

The synthetic cannabinoid O-1602 that does not bind significantly to CB~1~ or CB~2~ receptors, stimulates GTPγS activation in membranes from human recombinant GPR55-expressing cells (EC~50~ = 1.4 nM) ([@B49]; [@B20]). *In vivo*, O-1602 showed anti-inflammatory activity in mice with cerulein-induced acute pancreatitis characterized by an increased expression of GPR55 receptor ([@B62]). O-1602 has also been shown to increase levels of GPR18-mediated MAPK activity and calcium mobilization, but not β-arrestin signaling, thus supporting that O-1602 acts as a biased-agonist at GPR18 ([@B20]). Data have been reported suggesting the therapeutic potential of O-1602 for diseases related to the central nervous system ([@B6]), or to metabolic diseases ([@B102]).

Another minor component of *Cannabis sativa* is cannabigerol (CBG) ([@B36]). Structurally, CBG can be considered the cyclohexenyl-opened analog of CBD. Different therapeutic applications have been proposed for CBG, more recently CBG has been shown to have antibacterial action ([@B5]), antidepressant-like action ([@B24]), and anti-inflammatory properties for bowel disease ([@B13]). Molecular targets of CBG include the α~2~ adrenergic receptor, TRP channels, cyclooxygenase (COX-1 and COX-2) enzymes, as well as the 5-HT~1A~ and cannabinoid receptors ([@B18]; [@B21]; [@B104]). Cannabimovone is one of the latest natural phytocannabinoids that has been extracted from a cultivar of hemp rich in CBD ([@B115]). The terpenoid structure of cannabimovone replaces the cyclohexenyl ring of CBD by a functionalized cyclopentane including four contiguous stereocenters. Its total synthesis has been reported very recently ([@B17]). Cannabimovone is devoid of CB~1~ and CB~2~ activity, whereas it is a weak TPRV1 agonist.

Conclusion
==========

A significant amount of preclinical data has shown the high therapeutic potential of CBD especially in inflammatory mouse models. According to ClinicalTrials.gov records, CBD is currently tested in clinical phases for different inflammatory diseases. The results of the first clinical study of CDB for the treatment of inflammatory bowel have been published very recently. Unfortunately, the effects of CBD on Crohn's disease were ineffective in a randomized placebo-controlled trial on 20 patients probably due to low used doses ([@B84]). The potential antiepileptic effects of CBD in patients suffering seizures associated with Lennox--Gastaut syndrome and in children and young patients with Dravet syndrome are currently on-going. The research has tended to focus on CBD therapeutic applications. Less attention has been paid to the therapeutic utility of CBD derivatives.

Despite the identifications of CBD metabolites and naturally occurring CBD analogs, in general, their pharmacological properties have not been extensively studies. In what concerns synthetic CBD-based compounds, several of them have shown interesting pharmacological properties but none has been introduced into clinical trials yet. In a pharmacological point of view, whereas CBD does not have affinity for both classical CB~1~ and CB~2~ cannabinoid receptors, most of (+)-CBD derivatives do bind to CB~1~ and/or CB~2~ receptors. Others, such as Abn-CBD, O-1602, CBG, cannabimovone, ferruginene C, (-)-CBDV, and (-)-CBDA, have shown activity at other receptors including TPRV1, GPR35 and/or GPR18 receptors, or enzymes such as COX-2. A limitation of the development of CBD synthetic derivatives probably resides in the lack of a unique common molecular target.

In future therapeutic development of CBD derivatives, it will be prudent to take into account some structural considerations around the CBD scaffold. One of them is the possible atropisomerism around the phenyl--hexenyl bond. Ortho-substitution on the phenyl ring could have stereochemical consequences generating hindered rotation of the phenyl--hexenyl bond due to steric or electronic constraints, generating two isolable conformers in the case of slow interconversion ([@B9]; [@B32]). Thus, it is necessary to consider the implication of a possible atropoisomerism for new CBD analogs discovery ([@B19]).

The complexity of the pharmacological processes of CBD and CBD analogs suggest that a better understanding of their mechanism of action is required to devise successful synthetic CBD-based drug therapies.
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